HLUN-B Stock Analysis: H Lundbeck | CO
Drug Manufacturers - Specialty & Generic | CO, Denmark | Market Cap: 46.552m DKK | 12M Return: 6% | DK0061804770 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 33.2M
EPS Trend: 90.4%
Qual. Beats: 0
Rev. Trend: 99.5%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
H. Lundbeck A/S is a Danish pharmaceutical company founded in 1915 and headquartered in Valby, Denmark. It specializes in the research, development, manufacturing, and commercialization of treatments for psychiatric and neurological disorders, operating across Europe, the United States, and international markets.
The companys marketed portfolio includes Abilify Maintena/Abilify Asimtufii (schizophrenia, bipolar I disorder), Brintellix/Trintellix (depression), Rexulti/Rxulti (major depressive disorder, schizophrenia), Vyepti (migraine prevention), and Cipralex/Lexapro (depression), along with treatments for epilepsy, Parkinsons disease, dementia, and other CNS conditions. Its development pipeline spans multiple phases, with candidates targeting migraine, Parkinsons disease, post-traumatic stress disorder, developmental and epileptic encephalopathies, and synucleinopathies.
Lundbeck maintains a strategic research collaboration with Contera Pharma focused on developing oligonucleotide-based medicines for serious neurological conditions. As a mid-cap pharmaceutical firm in the GICS Health Care sector, the company operates in the specialized central nervous system (CNS) therapeutics niche, where long development timelines and patent protection are central to the business model.
- Trintellix and Rexulti drive US revenue growth in depression markets
- Vyepti migraine franchise expansion offsets legacy product declines
- Late-stage pipeline catalysts from Amlenetug and Bexicaserin Phase 3 readouts
| Net Income: 3.88b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.29 > 1.0 |
| NWC/Revenue: 13.40% < 20% (prev 19.07%; Δ -5.67% < -1%) |
| CFO/TA 0.10 > 3% & CFO 5.21b > Net Income 3.88b |
| Net Debt (7.68b) to EBITDA (8.25b): 0.93 < 3 |
| Current Ratio: 1.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (992.1m) vs 12m ago -0.37% < -2% |
| Gross Margin: 78.27% > 18% (prev 81.55%; Δ -3.27% > 0.5%) |
| Asset Turnover: 49.06% > 50% (prev 45.40%; Δ 3.66% > 0%) |
| Interest Coverage Ratio: 20.21 > 6 (EBIT TTM 5.86b / Interest Expense TTM 290.0m) |
| A: 0.07 (Total Current Assets 12.8b - Total Current Liabilities 9.37b) / Total Assets 52.7b |
| B: 0.50 (Retained Earnings 26.2b / Total Assets 52.7b) |
| C: 0.11 (EBIT TTM 5.86b / Avg Total Assets 52.3b) |
| D: 1.04 (Book Value of Equity 26.9b / Total Liabilities 25.8b) |
| Altman-Z'' = 3.89 = AA |
| DSRI: 1.04 (Receivables 6.23b/5.48b, Revenue 25.6b/23.5b) |
| GMI: 1.04 (GM 81.55% / 78.27%) |
| AQI: 0.99 (AQ_t 0.70 / AQ_t-1 0.71) |
| SGI: 1.09 (Revenue 25.6b / 23.5b) |
| TATA: -0.03 (NI 3.88b - CFO 5.21b) / TA 52.7b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of October 14, 2026, the stock is trading at DKK 46.92 with a total of 1,242,964 shares traded. Over the past week, the price has changed by +4.59%, over one month by +5.06%, over three months by +12.20% and over the past year by +5.97%.
Current recommended Stop Loss: 45.50 (which is 3% or 1.3 ATR below the current price).
H Lundbeck has no consensus analysts rating.
P/E Trailing = 12.0617
P/E Forward = 10.8814
P/S = 1.7932
P/B = 1.6232
P/EG = 8.0471
Revenue TTM = 25.6b DKK
EBIT TTM = 5.86b DKK
EBITDA TTM = 8.25b DKK
Long Term Debt = 8.96b DKK (from longTermDebt, last quarter)
Short Term Debt = 71.0m DKK (from shortTermDebt, last quarter)
Debt = 9.88b DKK (from shortLongTermDebtTotal, last quarter) + Leases 462.0m
Net Debt = 7.68b DKK (calculated: Debt 9.88b - CCE 2.20b)
Enterprise Value = 54.2b DKK (46.6b + Debt 9.88b - CCE 2.20b)
Interest Coverage Ratio = 20.21 (Ebit TTM 5.86b / Interest Expense TTM 290.0m)
EV/FCF = 11.70x (Enterprise Value 54.2b / FCF TTM 4.64b)
FCF Yield = 8.55% (FCF TTM 4.64b / Enterprise Value 54.2b)
FCF Margin = 18.09% (FCF TTM 4.64b / Revenue TTM 25.6b)
Net Margin = 15.13% (Net Income TTM 3.88b / Revenue TTM 25.6b)
Gross Margin = 78.27% ((Revenue TTM 25.6b - Cost of Revenue TTM 5.57b) / Revenue TTM)
Gross Margin QoQ = 79.00% (prev 80.03%)
Tobins Q-Ratio = 1.03 (Enterprise Value 54.2b / Total Assets 52.7b)
Interest Expense / Debt = 2.94% (Interest Expense 290.0m / Debt 9.88b)
Taxrate = 27.73% (1.49b / 5.37b)
NOPAT = 4.23b (EBIT 5.86b * (1 - 27.73%))
Current Ratio = 1.37 (Total Current Assets 12.8b / Total Current Liabilities 9.37b)
Debt / Equity = 0.37 (Debt 9.88b / totalStockholderEquity, last quarter 26.9b)
Debt / EBITDA = 0.93 (Net Debt 7.68b / EBITDA 8.25b)
Debt / FCF = 1.66 (Net Debt 7.68b / FCF TTM 4.64b)
Total Stockholder Equity = 25.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.43% (Net Income 3.88b / Total Assets 52.7b)
RoE = 15.13% (Net Income TTM 3.88b / Total Stockholder Equity 25.6b)
RoCE = 16.94% (EBIT 5.86b / Capital Employed (Equity 25.6b + L.T.Debt 8.96b))
RoIC = 10.05% (NOPAT 4.23b / Invested Capital 42.1b)
WACC = 6.90% (E(46.6b)/V(56.4b) * Re(7.91%) + D(9.88b)/V(56.4b) * Rd(2.94%) * (1-Tc(0.28)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.54 | Cagr: 0.01%
[DCF] Terminal Value 77.97% ; FCFF base≈3.92b ; Y1≈4.50b ; Y5≈6.62b
[DCF] Fair Price = 115.9 (EV 99.6b - Net Debt 7.68b = Equity 91.9b / Shares 793.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.37 | EPS CAGR: 20.99% | SUE: 0.20 | # QB: 0
Revenue Correlation: 99.51 | Revenue CAGR: 10.97% | SUE: 1.32 | # QB: 2
EPS current Quarter (2026-09-30): EPS=1.49 | Chg30d=-4.25% | Revisions=-40% | Analysts=6
EPS current Year (2026-12-31): EPS=6.31 | Chg30d=-0.34% | Revisions=-17% | GrowthEPS=+19.9% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=6.18 | Chg30d=-0.16% | Revisions=+29% | GrowthEPS=-2.0% | GrowthRev=+0.9%
[Analyst] Revisions Ratio: -8% (up=4, down=5)